• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    10/23/24 10:42:11 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care
    Get the next $SRDX alert in real time by email
    SC 13G/A 1 tm2426493d1_sc13ga.htm SC 13G/A

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         

    SCHEDULE 13G

    (Rule 13d-102)

     

    Information Statement Pursuant to Rules 13d-1

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    SURMODICS, INC.

    (Name of Issuer)

     

    Common Stock, Par Value of $0.05 Per Share

    (Title of Class of Securities)

     

    868873100

    (CUSIP Number)

     

    September 30, 2024

    Date of Event Which Requires Filing of the Statement

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 868873100 Schedule 13G Page 2 of 5

     

      1.

    Name of Reporting Person
    S.S. or I.R.S. Identification No. of Above Person

     

    Trigran Investments, L.P.

     
      2. Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Illinois limited partnership

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    141,221 shares of common stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    141,221 shares of common stock

     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    141,221 shares of common stock
     
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares o
     
      11. Percent of Class Represented by Amount in Row (9)
    Approximately 1.0% (based on 14,267,000 shares of common stock issued and outstanding as of July 26, 2024 pursuant to the Surmodics, Inc. Form 10-Q filed with the SEC on July 31, 2024)
     
      12. Type of Reporting Person
    PN

     

     

     

     

    CUSIP No. 868873100 Schedule 13G Page 3 of 5

     

     Item 1(a)

    Name of Issuer:

    Surmodics, Inc.

     
    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    9924 West 74th Street

    Eden Prairie, Minnesota 55344

     
    Item 2(a)

    Name of Person Filing

    See Item 2(c)

    Item 2(b)

    Address of Principal Business Office

    See Item 2(c)

    Item 2(c)

    Citizenship

    Trigran Investments, L.P.

    630 Dundee Road, Suite 230

    Northbrook, IL 60062

    Illinois limited partnership

    Item 2(d) Title of Class of Securities:
    Common Stock, par value of $0.05 per share
    Item 2(e) CUSIP Number:
    868873100

     

    Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under section 15 of the Exchange Act;
           
      (b) o Bank as defined in section 3(a)(6) of the Exchange Act;
           
      (c) o Insurance company as defined in section 3(a)(19) of the Exchange Act;
           
      (d) o Investment company registered under section 8 of the Investment Company Act;
           
      (e) o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act;
           
      (j) o A non-U.S. institution in accordance with Rule 13d–1(b)(1)(ii)(J);
           
      (k) o Group, in accordance with Rule 13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d–1(b)(1)(ii)(J), please specify the type of institution:_____________

     

    If this statement is filed pursuant to Rule 13d-1(c), check this box. x

     

     

     

     

    CUSIP No. 868873100 Schedule 13G Page 4 of 5

     

      Item 4 Ownership:
       
      (a)

    Amount beneficially owned:

    Incorporated by reference to Item 9 of the cover page pertaining to each reporting person.

      (b)

    Percent of class:

    Incorporated by reference to Item 11 of the cover page pertaining to each reporting person.

      (c) Number of shares as to which such person has:
        (i)

    Sole power to vote or to direct the vote:

    Incorporated by reference to Item 5 of the cover page pertaining to each reporting person.

        (ii)

    Shared power to vote or to direct the vote:

    Incorporated by reference to Item 6 of the cover page pertaining to each reporting person.

        (iii)

    Sole power to dispose or to direct the disposition of:

    Incorporated by reference to Item 7 of the cover page pertaining to each reporting person.

        (iv)

    Shared power to dispose or to direct the disposition of:

    Incorporated by reference to Item 8 of the cover page pertaining to each reporting person.

     

    Item 5 Ownership of Five Percent or Less of a Class:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.
     
    Item 6 Ownership of More than Five Percent on Behalf of Another Person:
       
      Not Applicable.
     
    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
      Not Applicable.
     
    Item 8 Identification and Classification of Members of the Group:
       
      Not Applicable.
     
    Item 9 Notice of Dissolution of Group:
       
      Not Applicable.
     
     Item 10 Certification:
       
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 868873100 Schedule 13G Page 5 of 5

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete, and correct.

     

    Dated this 23rd day of October, 2024

     

    TRIGRAN INVESTMENTS, L.P.  
       
    By: /s/ Lawrence A. Oberman  
    Name: Lawrence A. Oberman  
    Title: Executive Vice President of Trigran
    Investments, Inc., the General Partner of
    Trigran Investments, L.P.
     

     

     

     

    Get the next $SRDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRDX

    DatePrice TargetRatingAnalyst
    3/7/2025$43.00Hold → Buy
    Lake Street
    6/13/2023$36.00Hold → Buy
    Needham
    2/13/2023Buy → Hold
    Needham
    2/4/2022$70.00 → $58.00Buy
    Needham
    11/10/2021$76.00 → $70.00Buy
    Needham
    9/8/2021$68.00 → $76.00Buy
    Needham
    More analyst ratings

    $SRDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

      4/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als

      4/28/25 6:00:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

      European Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT™ Admiral™ DCB having 75% Higher Paclitaxel Dose. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were published in the March 2025 edition of the Eur

      4/22/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Financials

    Live finance-specific insights

    See more
    • Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

      4/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als

      4/28/25 6:00:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $28.7 million, a decrease of 3% year-over-year GAAP net loss of $(3.7) million, compared to $(0.8) million in the prior-year period Adjusted EBITDA(2) of $3.6 million, compared to $3.9 million in the prior-year period First Quarter and Recent Business Highlights On May 2

      1/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      11/14/24 3:36:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      11/6/24 1:30:21 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      10/23/24 10:43:41 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Leadership Updates

    Live Leadership Updates

    See more
    • KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting

      6/27/23 7:05:00 AM ET
      $KRMD
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heine Lisa Wipperman covered exercise/tax liability with 2,115 shares and exercised 2,640 shares at a strike of $27.30, increasing direct ownership by 4% to 13,978 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/20/25 4:12:56 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Director Dantzker David exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,216 shares, increasing direct ownership by 3% to 40,183 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/18/25 5:22:54 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Director Bedoya Jose H exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,224 shares, increasing direct ownership by 4% to 30,008 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/18/25 5:20:51 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    SEC Filings

    See more
    • SEC Form SD filed by Surmodics Inc.

      SD - SURMODICS INC (0000924717) (Filer)

      5/20/25 5:30:03 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Surmodics Inc.

      SCHEDULE 13G/A - SURMODICS INC (0000924717) (Subject)

      5/13/25 4:44:21 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Surmodics Inc.

      10-Q - SURMODICS INC (0000924717) (Filer)

      4/30/25 7:55:21 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Surmodics upgraded by Lake Street with a new price target

      Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00

      3/7/25 8:21:43 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics upgraded by Needham with a new price target

      Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00

      6/13/23 7:48:05 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics downgraded by Needham

      Needham downgraded Surmodics from Buy to Hold

      2/13/23 7:24:21 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care